An indicator of cancer: downregulation of Monoamine Oxidase-A in multiple organs and species

BackgroundIdentifying consistent changes in cellular function that occur in multiple types of cancer could revolutionize the way cancer is treated. Previous work has produced promising results such as the identification of p53. Recently drugs that affect serotonin reuptake were shown to reduce the risk of colon cancer in man. Here, we analyze an ensemble of cancer datasets focusing on genes involved in the serotonergic pathway. Genechip datasets consisting of cancerous tissue from human, mouse, rat, or zebrafish were extracted from the GEO database. We first compared gene expression between cancerous tissues and normal tissues for each type of cancer and then identified changes that were common to a variety of cancer types.ResultsOur analysis found that significant downregulation of MAO-A, the enzyme that metabolizes serotonin, occurred in multiple tissues from humans, rodents, and fish. MAO-A expression was decreased in 95.4% of human cancer patients and 94.2% of animal cancer cases compared to the non-cancerous controls.ConclusionThese are the first findings that identify a single reliable change in so many different cancers. Future studies should investigate links between MAO-A suppression and the development of cancer to determine the extent that MAO-A suppression contributes to increased cancer risk.

[1]  W. Rice.  ANALYZING TABLES OF STATISTICAL TESTS , 1989, Evolution; international journal of organic evolution.

[2]  F. Medeiros,et al.  Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. , 2007, Archives of pathology & laboratory medicine.

[3]  A. Flahault,et al.  [Could treatments with beta-blockers be associated with a reduction in cancer risk?]. , 2004, Revue d'epidemiologie et de sante publique.

[4]  C. Logothetis,et al.  Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. , 1994, Anticancer research.

[5]  K. Tsukidate,et al.  Toxicological response of rats to a novel monoamine oxidase type-A inhibitor, (5R)-3-[2-((1S)-3-cyano-1-hydroxypropyl)benzothiazol-6-yl]-5- methoxymethyl-2-oxazolidinone (E2011), orally administered for 13 weeks. , 1999, The Journal of toxicological sciences.

[6]  M. Nabissi,et al.  Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice. , 2004, Cancer letters.

[7]  Maria A Stalteri,et al.  Give me shelter: the global housing crisis. , 2003, BMC Bioinformatics.

[8]  D. Fuchs,et al.  Diminished quality of life in patients with cancer correlates with tryptophan degradation , 2007, Journal of Cancer Research and Clinical Oncology.

[9]  C. Bunce,et al.  Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. , 2003, Blood.

[10]  Karen J Wernli,et al.  Antidepressant medication use and breast cancer risk , 2009, Pharmacoepidemiology and drug safety.

[11]  M. Cole,et al.  Mechanism of transcriptional activation by the Myc oncoproteins. , 2006, Seminars in cancer biology.

[12]  J A Bean,et al.  A case-control study of breast cancer and psychotropic drug use. , 1982, Oncology.

[13]  Probal Banerjee,et al.  The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Cα , 2003 .

[14]  S. Senogles.  D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69 , 2007, Anti-cancer drugs.

[15]  J. Collet,et al.  Use of antidepressants and risk of colorectal cancer: a nested case-control study. , 2006, The Lancet. Oncology.

[16]  G. Superti-Furga,et al.  Selective serotonin reuptake inhibitors—A new modality for the treatment of lymphoma/leukaemia? , 2007 .

[17]  N. Volkow,et al.  Comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  E. Krenning,et al.  In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. , 2003, Cancer biotherapy & radiopharmaceuticals.

[19]  V. Karanikas,et al.  Tumor immune escape mediated by indoleamine 2,3-dioxygenase. , 2007, Immunology letters.

[20]  Yan-qin Liu,et al.  Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. , 2004, Acta pharmacologica Sinica.

[21]  Probal Banerjee,et al.  The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Calpha. , 2003, Biochimica et biophysica acta.

[22]  Y. Okazaki,et al.  Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT–PCR , 2004, British Journal of Cancer.

[23]  T. L. Drell,et al.  Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. , 2005, Current pharmaceutical design.

[24]  H. Sternbach.  Are antidepressants carcinogenic? A review of preclinical and clinical studies. , 2003, The Journal of clinical psychiatry.

[25]  P. Albert,et al.  5-HT1A-mediated promotion of mitogen-activated T and B cell survival and proliferation is associated with increased translocation of NF-κB to the nucleus , 2004, Brain, Behavior, and Immunity.

[26]  F. Landoni,et al.  Molecular characterisation of a panel of human ovarian carcinoma xenografts. , 1998, European Journal of Cancer.

[27]  T. Lumley,et al.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis , 2008, Breast Cancer Research and Treatment.

[28]  A. Khalil,et al.  Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. , 2000, Chemical research in toxicology.

[29]  D. Mikhailidis,et al.  The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation , 2006, BJU international.

[30]  P. Uotila.  The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer , 1996, Cancer Immunology, Immunotherapy.

[31]  J. Contessa,et al.  Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells , 2002, Oncogene.

[32]  S. Hernández-Díaz,et al.  Use of antidepressants and risk of lung cancer , 2007, Cancer Causes & Control.

[33]  Jiangang,et al.  Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. , 1992, Cancer research.

[34]  R. Gomez,et al.  Decreased expression of DARPP-32 in oral premalignant and malignant lesions. , 2007, Anticancer research.

[35]  J. Baron,et al.  Psychotropic medication use and risk of epithelial ovarian cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  R. Bremner,et al.  Insights from animal models on the origins and progression of retinoblastoma. , 2006, Current molecular medicine.

[37]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Liyuan,et al.  Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice , 2004 .

[39]  Liz Y. Han,et al.  Stress Hormone–Mediated Invasion of Ovarian Cancer Cells , 2006, Clinical Cancer Research.

[40]  A. Tankiewicz,et al.  Tryptophan and its metabolites in patients with oral squamous cell carcinoma: preliminary study. , 2006, Advances in medical sciences.

[41]  W. Stolz,et al.  Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. , 2005, The Journal of investigative dermatology.

[42]  T. Oyama,et al.  Expression of the p53 family in lung cancer. , 2006, Anticancer research.

[43]  D. Gabrilovich.  INGN 201 (Advexin®): adenoviral p53 gene therapy for cancer , 2006, Expert opinion on biological therapy.

[44]  A. Tesei,et al.  Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. , 2006, Journal of experimental therapeutics & oncology.

[45]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[46]  D. Holzschu,et al.  An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology , 2005, BMC women's health.